Pricing Log in Create free account
Saturday 17 October 2026 Export VIVS’s income statement to Excel — free account

VivoSim Labs, Inc.

VIVS Healthcare Biotechnology

VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.16 0.01 −5.88%
Market cap
$2.8M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
3/9
Altman Z
−71.71
Beneish M
29.46
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.00
Total sells 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 1 — —
Sell 1 — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.84
Revenue 0.11
Net Income (12.34)
Free Cash Flow (1.14)
Net Debt (1.67)
Current Ratio 1.70 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.21) (negative: loss-making)
P/S ratio 7.48
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 19.00% (at or above 15%: strong)
Next Y EPS Growth 2.60%
Next Y revenue growth 61.11% (at or above 10%: strong)
Next 5Y EPS Growth 22.32% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −7.4×, against a ten-year median of 13.8×; over the ten years it ranged from −60.2× in 2025 to 165× in 2016.
P/S against its own 10 years 3.54%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 3 11 5 2
Receivables 0 0 1 1
Inventory 0 — — —
Other — — — —
4 12 7 3
2024 2025 2026 Q'26
Payables 1 2 1 1
ST’ Debt — — — —
Other — 0 0 0
2 4 3 2

Compound Annual Growth %

10y 5y 3y
Sales (13.69%) (43.10%) (29.26%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Jun Sep Dec Mar Year
’26 0 — — — —
’26 0 0 0 0 0
’25 0 0 0 0 0
’24 0 — 0 0 0
’23 — 0 0 0 0
’22 — — — 2 2
’20 1 1 0 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (3) — — — —
’26 (4) (2) (2) (2) (11)
’25 (3) (3) (2) (2) (9)
’24 (5) (3) (4) (3) (15)
’23 (2) (2) (3) (5) (12)
’22 (1) (2) (3) (2) (8)
’21 (3) (7) (1) (2) (13)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (3) — — — —
’26 (4) (2) (2) (2) (11)
’25 (3) (3) (2) 7 0
’24 (5) (3) (4) (3) (15)
’23 (2) (2) (3) (5) (13)
’22 (2) (2) (3) (2) (9)
’21 (3) (7) (2) (2) (14)
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 (0.25) — — — —
’26 (1.14) (0.98) (1.03) (2.21) (5.35)
’25 (2.76) (1.68) (2.28) 5.03 (1.70)
’24 (5.52) (5.52) (4.80) (3.48) (19.21)
’23 (4.44) (4.56) (4.44) (10.20) (23.77)
’22 (3.48) (4.80) (4.80) (2.64) (15.85)
’21 (4.80) (16.37) (4.44) (3.60) (29.29)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 316.80 216.00 52.80 45.60 43.56 16.44 12.00 3.84 1.41 0.15

Analyst estimates 2027–2029

Powerpack
High 940.80 501.60 283.20 245.88 287.04 56.04 40.80 20.88 21.96 3.40
People
People Employees 113 75 61 6 9 18 24 20 13 15
Revenue/emp, $m 0.04 0.06 0.05 0.37 0.00 0.08 0.02 0.01 0.01 0.01
Income, $m
Income, $m Revenue 4 5 3 2 — 2 0 0 0 0
Gross margin, % 77.40 77.62 84.41 85.06 0.00 100.00 100.00 100.00 96.53 100.00
EBT (38) (35) (27) (19) (17) (11) (17) (15) (2) (14)
EBT margin, % (908.37) (756.05) (861.60) (851.91) 0.00 (763.07) (4,664.05) (13,457.80) (1,726.39) (10,565.65)
Net income (38) (35) (27) (19) (17) (11) (17) (15) (2) (14)
Depreciation 1 1 1 1 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 10.39 10.30 6.43 4.07 0.00 2.07 0.51 0.14 0.10 0.05
Earnings (93.64) (76.83) (55.22) (34.46) (29.29) (15.85) (23.77) (19.21) (1.70) (5.35)
Cash flow (71.67) (64.60) (42.39) (27.58) (23.17) (11.66) (17.10) (19.23) (6.46) (4.18)
Capex (3.30) (0.65) (0.16) 1.38 (0.68) (0.56) (0.55) (0.06) 6.14 0.00
Free cash flow (74.97) (65.25) (42.55) (26.20) (23.86) (12.22) (17.64) (19.28) (0.32) (4.18)
Book value 153.15 99.81 75.53 49.35 68.18 41.67 21.12 4.73 7.17 (0.42)
Shares, m 0 0 0 1 1 1 1 1 1 3
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00
P/S 73.47 22.13 36.20 24.18 — 10.80 10.20 34.75 22.77 28.25
P/B 4.98 2.28 3.08 1.99 — 1.08 1.24 2.62 0.31 0.00
EV/Sales 58.63 12.63 24.40 11.72 — 1.33 1.64 24.05 (55.78) (10.09)
EV/FCF (8.10) (1.99) (3.67) (1.81) — (0.45) (0.24) (0.44) 14.76 0.69
Cash, $m
Cash, $m Operating cash flow (29) (29) (20) (15) (13) (8) (12) (15) (9) (11)
Capex (1) 0 0 1 0 0 0 0 9 —
Free cash flow (31) (29) (20) (14) (14) (9) (13) (15) 0 (11)
Balance, $m
Balance, $m Working capital 59 42 35 27 38 28 13 2 8 4
Total debt — — — — — 2 2 — — —
Net debt (63) (44) (36) (27) (37) (29) (16) (3) (11) (5)
Shareholders’ equity 62 45 36 27 39 30 15 4 10 (1)
Returns, %
Returns, % ROA (56.23) (58.49) (58.89) (54.18) (49.23) (31.27) (64.39) (110.05) (23.70) (125.64)
ROIC 0.00 (2,563.30) 0.00 0.00 (574.03) (467.69) 0.00 (1,346.96) 0.00 0.00
ROE (61.74) (65.08) (65.86) (59.46) (51.12) (32.99) (75.80) (155.00) (35.31) (294.75)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

VivoSim Labs, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ARAV ARAVIVE, INC $3.0M — (loss-making) — (loss-making) −44.39% (below 0%: shrinking) n/m +48.19% (above 0%: growing) 100.00% (323.44%) Compare
DCOY Decoy Therapeutics Inc $2.9M 0.0× — (loss-making) −84.61% (below 0%: shrinking) n/m −212.47% (below 0%: shrinking) 100.00% (1,055.98%) Compare
MBIO Mustang Bio, Inc. $2.9M — (loss-making) — — n/m +27.78% (above 0%: growing) 0.00% 0.00% Compare
BCAB BioAtla, Inc. $2.9M — (loss-making) — (loss-making) +4,233.33% (above 0%: growing) n/m +97.03% (above 0%: growing) 100.00% 3.49% Compare
ONCO Onconetix, Inc. $2.9M 0.0× — (loss-making) −83.94% (below 0%: shrinking) n/m −36.00% (below 0%: shrinking) 25.15% (15,969.59%) Compare
VIVS VivoSim Labs, Inc. $2.8M — (loss-making) — (loss-making) −51.35% (below 0%: shrinking) n/m +17.87% (above 0%: growing) 100.00% (15,327.78%)
AFMDQ Affimed N.V. $2.8M — (loss-making) — (loss-making) −92.02% (below 0%: shrinking) n/m +46.95% (above 0%: growing) 100.00% (9,216.90%) Compare
HCWB HCW Biologics Inc. $2.8M — (loss-making) — (loss-making) +1,954.55% (above 0%: growing) n/m −20.84% (below 0%: shrinking) (69.25%) (2,335.03%) Compare
SLXN Silexion Therapeutics Corp $2.7M — (loss-making) — — n/m −16.63% (below 0%: shrinking) — 0.00% Compare
Median of peers $2.9M — — −64.16% — +5.57% 100.00% (689.71%)

All 614 Biotechnology stocks →

VivoSim Labs, Inc. (VIVS) key facts

  • Concern: VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025.
  • VivoSim Labs, Inc. (VIVS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, VIVS traded at $0.16, a market capitalization of $2.8 million.
  • Return on equity was −294.8% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −71.71 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

VivoSim Labs, Inc. (VIVS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/VIVS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com